Solution structure and in Silico binding of a cyclic peptide with hepatitis B surface antigen by Muhamad, Azira et al.
Solution structure and in Silico binding of a cyclic peptide with hepatitis B surface 
antigen 
 
ABSTRACT 
A specific ligand targeting the immunodominant region of hepatitis B virus is desired in 
neutralizing the infectivity of the virus. In a previous study, a disulfide constrained cyclic 
peptide cyclo S1,S9 Cys-Glu-Thr-Gly-Ala-Lys-Pro-His-Cys (S1, S9-cyclo-CETGAKPHC) 
was isolated from a phage displayed cyclic peptide library using an affinity selection method 
against hepatitis B surface antigen. The cyclic peptide binds tightly to hepatitis B surface 
antigen with a relative dissociation constant (KDrel) of 2.9 nm. The binding site of the 
peptide was located at the immunodominant region on hepatitis B surface antigen. 
Consequently, this study was aimed to elucidate the structure of the cyclic peptide and its 
interaction with hepatitis B surface antigen in silico. The solution structure of this cyclic 
peptide was solved using 1H, 13C, and 15N NMR spectroscopy and molecular dynamics 
simulations with NMR-derived distance and torsion angle restraints. The cyclic peptide 
adopted two distinct conformations due to the isomerization of the Pro residue with one 
structured region in the ETGA sequence. Docking studies of the peptide ensemble with a 
model structure of hepatitis B surface antigen revealed that the cyclic peptide can potentially 
be developed as a therapeutic drug that inhibits the virus–host interactions. 
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